Skip to main content

CORRECTION article

Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1540165

Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count

Provisionally accepted
Rocío Del Campo-Pedrosa Rocío Del Campo-Pedrosa 1,2*Alfonso Martín Carnicero Alfonso Martín Carnicero 3Ana González Marcos Ana González Marcos 2Alfredo Martínez Alfredo Martínez 4
  • 1 Encore Lab SL, Logroño, Spain
  • 2 University of La Rioja, Logroño, La Rioja, Spain
  • 3 Hospital San Pedro, Logroño, La Rioja, Spain
  • 4 Centro de Investigación Biomédica de La Rioja, Logroño, La Rioja, Spain

This article is a correction to:

  1. New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count

    1. Read original article

The final, formatted version of the article will be published soon.

    In the published article, there was an error in Table 4 as published. Error was in the manual transcription of the numerical data of the Kaplan-Meier result. Specifically, the transcription error has occurred for the rows of ALP, GGT and LDH. The corrected The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. In the published article, there was an error. The error corresponds to the paragraph in which numerical references are made to the Table 4 with the numerical transcription error.A correction has been made to 3 Results, 3.3 Prognosis, 3 rd paragraph. This sentence previously stated:"Those individuals whose values on GGT and LDH were below the cut-off point (Table 4) presented a better prognosis than the ones who were above; specifically, they presented an OS increase by 44.8%, and 74.6%, respectively (Figures 1B,C). For their part, ALP<102.00 (Figure 1A), number of leukocytes<8,000, neutrophiles<6,000 and monocytes<800 (Figures 1D-F) were also statistically significant, resulting in patients with low levels increasing their survival by 49.7%, 44.9%, 42.5% and 44.4%, respectively (Table 4)."

    Keywords: Prognosis model, Prognostic biomarkers, overall survival, Gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), advanced and metastatic pancreatic cancer, Pancreatic ductal adenocarcinoma (PDAC)

    Received: 05 Dec 2024; Accepted: 16 Dec 2024.

    Copyright: © 2024 Del Campo-Pedrosa, Martín Carnicero, González Marcos and Martínez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rocío Del Campo-Pedrosa, Encore Lab SL, Logroño, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.